Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

"Multicenter, prospective, open label study , in patients with non small cell lung cancer (NSCLC), stage IIIB / IV or recurrent, after the failure of first line chemotherapy in which it's possible a treatment that evaluates the effectiveness and the safety of oral BIBF 1120 in combination with standard docetaxel therapy, which can be administered (at the discretion of the referring physician) with tri-weekly or weekly schedule

Next Previous
Trial Profile

"Multicenter, prospective, open label study , in patients with non small cell lung cancer (NSCLC), stage IIIB / IV or recurrent, after the failure of first line chemotherapy in which it's possible a treatment that evaluates the effectiveness and the safety of oral BIBF 1120 in combination with standard docetaxel therapy, which can be administered (at the discretion of the referring physician) with tri-weekly or weekly schedule

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SENECA

Most Recent Events

  • 10 Sep 2019 Status changed to active, no longer recruiting as per results presented at the 20th World Conference on Lung Cancer
  • 10 Sep 2019 Results evaluating 16 patients previously treated with immunotherapy and comparing them to the rest of patient population presented at the 20th World Conference on Lung Cancer
  • 26 Sep 2018 Results (From January 2016 to data cut-off, on 30th March 2018, n= 197) presented at the 19th World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top